Complex Journey from Innovation to Patient impact
Beyond Reporting - Safety surveillance analytics for medical devices...
From Snapshots to Movies
Elevating Drug Safety
Electronic Logs - The next phase of execution maturity in pharma
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
Combating the FWA Menace
In the complex landscape of Pharmacy Benefit Management PBM combatting Fraud Waste and Abuse FWA has emerged as a critical challenge This article explores innovative realtime techniques for PBMs to navigate the intricacies of FWA and Medicare noncompliance
Research Insights
Identifying Severe COVID-19 Risk Variants Modulating Enhancer Reporter Activity in Lung Cells
Common genetic variants contribute to risk for complex human diseases However despite thousands of associations variants modulating disease risk and their functional impact remain largely unknown
Case Studies
Out-Of-Hours Antibiotic Prescription After Screening With C Reactive Protein: A Randomised Controlled Case Study
Abstract Fever respiratory symptoms and infections are common among children in primary care especially at outofhours OOH services Serious infections have low prevalence in primary care and even more so after introduction of vaccines for Haemophilus influenzae type B and pneumococcal conjugate vaccines It is challenging for clinicians to distinguish se
Techno Trends
Ipsen Developed First-of-its-kind for Metastatic Pancreatic Adenocarcinoma
Ipsen has developed a groundbreaking treatment called Onivyde in combination with oxaliplatin fluorouracil and leucovorin for adults with metastatic pancreatic adenocarcinoma as a firstline therapy
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Emergence of Organ-on-chips for Diseases Studies and Drug Development
Giuseppe Maruccio is Full Professor at Department of Mathematics and Physics – University of Salento and head of Omnics Research Group which comprises researchers with different backgrounds from physics to life sciences working in cross-disciplinary areas with applications from -onics (electronics, spintronics and magnonics) to -omics technologies (genomics, proteomics and cellomics)
Anna Grazia Monteduro is researcher at Department of Mathematics and Physics - University of Salento in Lecce (Italy) and carries out her research activity within Omnics Research Group in the fields of (i) sensors, lab on chip and organ on chip; (ii) Nanoelectronics, spintronics, nanomagnetism and applied superconductivity.
Silvia Rizzato is researcher at the Department of Mathematics and Physics - University of Salento and carries out her research activity within Omnics Research Group on the development of new devices and processes for sensing and spintronics, including surface acoustic waves devices, electrochemical sensors and colloidal lithography for LSPR sensors.
Giusi Caragnano is a PhD student in Nanotechnologies at the University of Salento - CNR Nanotec and she is part of the Omnics Research Group. Her research activity concerns development of the Organ-on-chip to support the treatment of both chronic and cancerous gastrointestinal diseases
Novel Developments in Drug Delivery Systems
Saina Bijanzadeh is a chemist specializing in nanomaterial-based drug delivery and biomedical applications. She has research experience in nanoparticle synthesis, MOF platforms, and drug release systems, with published work in international journals. Her interests focus on innovative therapeutic delivery strategies and interdisciplinary pharmaceutical and bio(medical)engineering research.
The Unknown Sources of Error in the Pharmaceutical Weighing Process
Thomas Caratsch has been the Head of Laboratory Division since December 2007 at the company's headquarters in Greifensee, Switzerland. Prior to joining the company, Caratsch held various management positions within the Hoffmann La Roche group in the U.S. and Switzerland, including General Manager of Roche Instrument Centre AG and Head of Disetronic Medical Systems AG. He began his career as a development engineer at Sodeco-Saia in Geneva.
Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)
is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.
Artificial Intelligence
Assistant Professor, Department of Pharmaceutics, L. M.College of Pharmacy
L. M.College of Pharmacy
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
